Regeneron Pharmaceuticals, Inc. (REGN)

As of Dec 31, 2024, Regeneron Pharmaceuticals, Inc.'s fair value using the Ben Graham formula is $964.2 per share. This is calculated using Ben Graham formula, where EPS is $40.9 and BVPS (Book Value Per Share) is $323.4. The current price of $700.3 suggests Regeneron Pharmaceuticals, Inc. may be overvalued by this conservative metric.

Regeneron Pharmaceuticals, Inc. earnings per share (EPS) for the twelve months ending Dec 31, 2024, was $40.9, a 9.5% growth year-over-year.

Regeneron Pharmaceuticals, Inc.'s margin of safety is positive 37.7%, calculated as (Graham Number - Current Price) / Current Price. A negative margin of safety suggests the stock doesn't provide the level of safety Graham typically sought in his investments.